Core Viewpoint - A class action lawsuit has been filed against iRobot Corporation for alleged violations of federal securities laws during the specified class period [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased iRobot securities between January 29, 2024, and March 11, 2025 [2]. - The complaint alleges that iRobot made materially false and misleading statements regarding its business operations and prospects, particularly concerning the impact of its Restructuring Plan and the termination of the Amazon Acquisition [3]. Group 2: Allegations Against iRobot - The complaint claims that iRobot overstated the effectiveness of its Restructuring Plan in maintaining stability post-Amazon Acquisition [3]. - It is alleged that iRobot is unlikely to operate profitably as a standalone company, raising doubts about its ability to continue as a going concern [3]. - The public statements made by iRobot's executives are claimed to be materially false and misleading throughout the class period [3]. Group 3: Next Steps for Investors - Investors who suffered losses in iRobot have until September 5, 2025, to request to be appointed as lead plaintiff in the case [4]. - A copy of the complaint can be reviewed on the law firm's website [4]. Group 4: Legal Representation - The law firm representing the investors operates on a contingency fee basis, meaning they will only collect fees if the case is successful [5]. - Bronstein, Gewirtz & Grossman, LLC has a history of recovering substantial amounts for investors in securities fraud cases [6].

Group 1 - Halper Sadeh LLC is investigating CARGO Therapeutics, Inc. for potential violations of federal securities laws related to its sale to Concentra Biosciences, LLC, which is proposed at $4.379 in cash per share plus a contingent value right [1] - WNS (Holdings) Limited is also under investigation for its sale to Capgemini at $76.50 per share [2] - The firm may seek increased consideration for shareholders and additional disclosures regarding the proposed transactions [3] Group 2 - Shareholders are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options without any out-of-pocket payment for legal fees [4] - Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, recovering millions for defrauded investors [4]

Core Viewpoint - A class action lawsuit has been filed against Organon & Co. for alleged violations of the Securities Exchange Act of 1934, claiming misleading statements regarding the company's financial health and projections during the Class Period from November 3, 2022, to April 30, 2025 [1][4]. Company Overview - Organon develops and delivers health solutions through prescription therapies and medical devices [3]. Allegations of the Lawsuit - The lawsuit alleges that Organon misrepresented the risk of loss of exclusivity and price erosion for its product Nexplanon, leading to inflated sales growth expectations that would not reach $1 billion by the end of fiscal year 2025 [4]. - It is claimed that Organon was not on track to achieve a $1 billion milestone payment from Merck & Co. related to Nexplanon sales, nor maintain the required $1 billion in free cash flow to sustain its dividend [4]. - The lawsuit further asserts that Organon might not maintain its corporate debt ratings and lacked a reasonable basis for reporting its business metrics and financial projections during the Class Period [4]. Financial Impact - Following the announcement of its first quarter 2025 financial results, Organon reduced its dividend by 90%, from $1.16 per share annually to $0.08 per share annually, which resulted in a stock price drop of over 27% [5].

Core Viewpoint - Iovance Biotherapeutics Inc. is undergoing a leadership transition with the resignation of CFO Jean-Marc Bellemin amid commercial challenges and a class-action lawsuit related to its flagship drug Amtagvi [1][2][3]. Group 1: Leadership Transition - CFO Jean-Marc Bellemin will resign effective July 10, 2025, to pursue other endeavors, having held the position since November 2020 [1][2]. - The company has not yet named a successor for the CFO role, creating uncertainty during a challenging period [2]. Group 2: Commercial Challenges - Iovance's first-quarter sales for Amtagvi significantly underperformed expectations, leading to a downward revision of full-year revenue projections [3]. - The company's stock price fell over 44%, from $3.17 on May 8, 2025, to $1.75 by the close of trading on May 9, 2025, reflecting investor concerns about commercial execution [7]. Group 3: Legal Issues - Iovance is facing a class-action lawsuit alleging securities fraud related to the company's portrayal of its authorized treatment centers (ATCs) and their role in driving demand for Amtagvi [4][5]. - The lawsuit claims that ATCs experienced delays in initiating treatments and inefficiencies in patient selection, leading to higher patient drop-off rates [5][6]. - Hagens Berman is investigating the allegations to determine if the company's public statements were consistent with internal realities [8].

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between April 29, 2025, and June 23, 2025 [1][2] Group 1: Allegations and Impact - The lawsuit claims that Hims was involved in the deceptive promotion and sale of illegitimate versions of Wegovy®, which posed risks to patient safety [2] - It is alleged that this situation created a substantial risk of termination of Hims' collaboration with Novo Nordisk [2] - The defendants' positive statements regarding the Company's business and prospects are claimed to be materially misleading and lacking a reasonable basis [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until August 25, 2025, to request appointment as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4]

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to the safety and clinical trial protocol of its RP-A501 treatment, which resulted in a significant stock price decline after the FDA placed a clinical hold on the study [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for investors affected by alleged securities fraud between February 27, 2025, and May 26, 2025 [1]. - Defendants allegedly provided misleading statements about the safety of RP-A501 while concealing serious adverse events, including participant deaths during the clinical trial [2]. - Following the announcement of the FDA's clinical hold on May 27, 2025, Rocket's stock price plummeted from $6.27 to $2.33 per share, a decline of approximately 37% in one trading day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant time frame have until August 11, 2025, to request appointment as lead plaintiff, although participation does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as a leading securities litigation firm in the United States [4].

NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Reddit, Inc. ("Reddit, Inc." or the "Company") (NYSE: RDDT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Reddit, Inc. investors who were adversely affected by alleged securities fraud between October 29, 2024 and May 20, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/reddit-inc-lawsuit-submis ...

Core Viewpoint - A class action securities lawsuit has been filed against Krispy Kreme, alleging securities fraud that negatively impacted investors between March 26, 2024, and May 7, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Krispy Kreme's management made overly positive statements while concealing adverse facts about the demand for its products at McDonald's locations [2] - It is alleged that lower demand at McDonald's led to declining average weekly sales per store, and the partnership with McDonald's was not profitable, causing Krispy Kreme to pause expansion plans [2] - Krispy Kreme reported a net revenue decline of $404 million, or 10.4%, and a decrease in average sales per store due to changing customer preferences [2] Group 2: Stock Price Impact - Following the release of disappointing financial results on February 25, 2025, Krispy Kreme's stock price fell from $9.13 to $7.13 per share [2] - On May 8, 2025, the company announced a first-quarter 2025 net revenue of $375.2 million, a decline of 15.3% or $67.5 million, leading to a further stock price drop from $4.33 to $3.26 per share, a decrease of about 25% in one day [2] Group 3: Next Steps for Investors - Investors who suffered losses during the relevant period have until July 15, 2025, to request to be appointed as lead plaintiff in the lawsuit [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 4: Firm Background - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4] - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

Core Viewpoint - A class action securities lawsuit has been filed against Compass Group Diversified Holdings, LLC due to alleged securities fraud affecting investors between February 24, 2022, and May 7, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Compass Diversified failed to disclose effective internal controls over financial reporting and critical information regarding its subsidiary, Lugano Holding, Inc., which had undisclosed financing arrangements and irregularities in sales, cost of sales, inventory, and accounts receivable [2]. - The truth about these issues emerged on May 7, 2025, when Compass announced that its financial statements for fiscal 2024 could no longer be relied upon due to an internal investigation into Lugano, leading to a significant drop in stock price from $17.25 to $6.55 per share [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant time frame have until July 8, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [4].

Core Viewpoint - A class action securities lawsuit has been filed against Bitfarms Ltd. alleging securities fraud that affected investors between March 21, 2023, and December 9, 2024 [1][2]. Group 1: Allegations and Financial Misstatements - The lawsuit claims that Bitfarms had inadequate internal controls over financial reporting [2]. - It is alleged that the company misclassified proceeds from the sale of digital assets, categorizing them as cash flow from operating activities instead of investing activities [2]. - The complaint states that Bitfarms overstated its ability to remediate material weaknesses in its internal controls related to the classification of the 2021 Warrants [2]. - These errors led to misstatements in several previously issued financial statements, which are now deemed inaccurate and likely to require restatement [2]. - As a result, the company's public statements were materially false and misleading during the relevant period [2]. Group 2: Legal Process and Participation - Investors who suffered losses in Bitfarms Ltd. during the specified timeframe have until July 8, 2025, to request appointment as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].